Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9920 Pacific Heights Blvd, Suite 350, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.38K % +60.9%
Debt-to-equity 3.13 % -41.3%
Return On Equity -12.1 % +56.6%
Return On Assets -11.7 % +55.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares +11.7%
Common Stock, Shares, Outstanding 112M shares +11.4%
Entity Public Float 4B USD +4174%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 109M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 109M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 102M USD +59.3%
General and Administrative Expense 49.3M USD +33.1%
Operating Income (Loss) -151M USD -49.7%
Net Income (Loss) Attributable to Parent -110M USD -28%
Earnings Per Share, Basic -1.01 USD/shares -11%
Earnings Per Share, Diluted -1.01 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.7M USD -51.9%
Assets, Current 907M USD +147%
Operating Lease, Right-of-Use Asset 1M USD -10.9%
Assets 908M USD +146%
Accounts Payable, Current 9.81M USD +30.6%
Liabilities, Current 27.4M USD +43.3%
Operating Lease, Liability, Noncurrent 630K USD -32.7%
Liabilities 28M USD +39.7%
Retained Earnings (Accumulated Deficit) -488M USD -29.1%
Stockholders' Equity Attributable to Parent 880M USD +153%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 880M USD +153%
Liabilities and Equity 908M USD +146%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.13M USD +75.1%
Net Cash Provided by (Used in) Financing Activities 606M USD +14385%
Net Cash Provided by (Used in) Investing Activities -460M USD -21019%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 112M shares +11.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3M USD -31.2%
Deferred Tax Assets, Valuation Allowance 164M USD +37.9%
Deferred Tax Assets, Gross 164M USD +37.8%
Operating Lease, Liability 1.12M USD -11.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -110M USD -29.6%
Operating Lease, Liability, Current 489K USD +50.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure +33.3%
Deferred Tax Assets, Operating Loss Carryforwards 40.8M USD +55.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 281K USD -10.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%